Page last updated: 2024-09-05

erlotinib hydrochloride and Glioblastoma

erlotinib hydrochloride has been researched along with Glioblastoma in 88 studies

Research

Studies (88)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	24 (27.27)	29.6817
2010's	53 (60.23)	24.3611
2020's	11 (12.50)	2.80

Authors

Authors	Studies
Bagherian, A; Masoudian, N; Mirzaei, H; Roudi, B	1
Amini, R; Bayat, M; Karami, H	1
Cui, H; Geng, S; Hou, J; Hu, X; Liang, H; Peng, W; Shi, S; Sun, X; Wang, F; Zhang, J; Zhong, D; Zhong, J	1
Humphreys, IR; Ishmael, JE; Mattos, DR; McPhail, KL; Nguyen, MH; Serrill, JD; Smith, AB; Viollet, B; Wan, X	1
Liang, Y; Meng, F; Qiao, Z; Zhi, S	1
Chen, M; Desprez, PY; Dickinson, L; Dighe, P; Galvez, L; Ice, RJ; Jian, D; Kashani-Sabet, M; Leng, L; McAllister, SD; Nosrati, M; Rodriguez-Brotons, A; Sidorov, M; Soroceanu, L; Vaquero, E; Woo, RWL	1
An, Z; Fan, QW; Haas-Kogan, DA; Lu, M; Luo, X; Phillips, JJ; Shokat, KM; Weiss, WA; Wong, RA	1
Alamdari-Palangi, V; Amini, R; Karami, H	1
Catapano, J; Czyż, J; Król, K; Pudełek, M; Ryszawy, D; Wróbel, T	1
Cenci, T; D'Alessandris, QG; DI Bonaventura, R; Larocca, LM; Lauretti, L; Martini, M; Montano, N; Olivi, A; Pallini, R; Stumpo, V	1
Alamdari-Palangi, V; Baazm, M; Karami, H; Karami, Z	1
Bartom, E; Bi, Y; Burant, CF; Calvert, AE; Chalastanis, A; Chandel, NS; Davuluri, RV; Dubrovskyi, O; Horbinski, C; Hua, Y; Hurley, LA; James, CD; Kachman, M; Kouri, FM; May, JL; Mazar, AP; Mishra, RK; Peter, ME; Schiltz, GE; Stegh, AH; Wu, Y; Zheng, H	1
Hanselman, JS; Harley, BAC; Pedron, S; Sarkaria, JN; Schroeder, MA	1
Ahmadian, S; Alimoghaddam, K; Ghaffari, SH; Ghavamzadeh, A; Mesbahi, Y; Zekri, A	1
Li, B; Li, Y; Liu, J; Liu, S; Tang, Y; Yuan, D; Yuan, X	1
Baxa, U; Majumder, P; Schneider, JP; Walsh, STR	1
Lakkadwala, S; Singh, J	1
Cenci, T; D'Alessandris, QG; Fernandez, E; Larocca, LM; Lauretti, L; Martini, M; Montano, N; Olivi, A; Pallini, R; Pignotti, F; Stumpo, V	1
Abdelmoula, WM; Agar, JN; Agar, NYR; Calligaris, D; Carlson, BL; Elmquist, WF; Emdal, KB; Gupta, SK; Jackson, PR; Johnson, AJ; Joughin, BA; Kellersberger, KA; Kim, M; Kolluri, A; Laramy, JK; Lauffenburger, DA; Lu, FK; Mladek, AC; Peng, S; Randall, EC; Reddy, RJ; Regan, MS; Roos, A; Sarkaria, JN; Swanson, KR; Tran, NL; White, FM; Xie, XS	1
Brell, M; Fernández de Mattos, S; Ramis, G; Serra-Sitjar, M; Villalonga, P; Villalonga-Planells, R	1
Dos Santos Rodrigues, B; Lakkadwala, S; Singh, J; Sun, C	1
Chen, JE; Harley, BAC; Laken, SE; Pedron, S; Sarkaria, JN; Wolter, GL	1
Akhavan, D; Babic, I; Bensinger, SJ; Cavenee, WK; Cloughesy, TF; Dang, J; Flagg, M; James, CD; Kornblum, HI; Mischel, PS; Nael, A; Nathanson, D; Nourian, AA; Pourzia, AL; Sasayama, T; Tamanoi, F; Tanaka, K; Villa, GR; Vinters, HV; Williams, KJ; Yang, H; Yong, WH	1
Cavenee, WK; Cloughesy, TF; Iwanami, A; Mischel, PS	1
Bachem, MG; Debatin, KM; Dwucet, A; Halatsch, ME; Karpel-Massler, G; Kast, RE; Nonnenmacher, L; Westhoff, MA; Wirtz, CR; Zhou, S	1
Kathagen, A; Kolbe, K; Lamszus, K; Liffers, K; Merlo, A; Riethdorf, S; Schulte, A; Westphal, M; Zapf, S	1
Chen, Y; Fisher, CJ; Kuta, V; Lai, B; Lilge, LD; Niu, CJ	1
Cavenee, WK; Cloughesy, TF; Eskin, A; Furnari, FB; Gini, B; Gomez, G; Heath, JR; Hwang, K; James, CD; Koga, T; Kornblum, HI; Masui, K; Mischel, PS; Mottahedeh, J; Nathanson, DA; Nelson, SF; Ohashi, M; Paucar, A; Rao, PN; Reed, R; Visnyei, K; Wang, J; Wykosky, J; Yang, H; Zhu, S	1
Butowski, NA; Chang, SM; Clarke, JL; Costello, JF; DeSilva, AA; Molinaro, AM; Perry, A; Phillips, JJ; Prados, MD; Rabbitt, JE	1
Addeo, R; Caraglia, M; Parlato, C; Zappavigna, S	1
Aldape, K; Berens, ME; Carrera-Silva, EA; Dietrich, JD; Errasti, AE; Ghosh, S; Gibbs, D; Hulme, C; Kusne, Y; Loftus, JC; Lu, Z; Mandell, EK; Perry, AS; Rothlin, CV; Rushing, EJ; Sanai, N; Yang, W	1
Brown, D; Butowski, N; Cheng, SY; Giles, FJ; James, CD; Mazar, AP; Nicolaides, T; Ozawa, T; Parsa, AT; Raizer, JJ; Sarkaria, JN; Shen, W; Stegh, AH; Yao, TW; Yoshida, Y	1
Chang, SM; Clarke, J; Jalilian, L; Lupo, JM; Molinaro, AM; Nelson, SJ; Prados, M; Wen, Q	1
Cavenee, WK; Chen, CC; Furnari, FB; Gomez, GG; Gonias, SL; Hu, J; Mischel, PS; Pizzo, D; Taylor, T; Thorne, AH; VandenBerg, SR; Villa, GR; Wykosky, J	1
Bauer, R; Efferth, T; Kretschmer, N; Zhao, Q	1
Heath, JR; Kim, J; Mai, WX; Nathanson, DA; Shin, YS; Su, Y; Wei, W; Xue, M	1
Kolbe, K; Lamszus, K; Liffers, K; Schulte, A; Westphal, M	1
Doussau, A; Ezzalfani, M; Paoletti, X; Rizzo, E; Thiébaut, R	1
Ascierto, ML; Berens, ME; Briggs, M; Johnson, J; Kang, L; Marincola, FM; Mittal, S; Newsome, D; Tanner, K; Vande Woude, GF; Xie, Q	1
Aldape, K; Chamberlain, M; Conrad, C; De Groot, J; Giglio, P; Gilbert, MR; Grimm, S; Groves, M; Hu, J; Liu, D; Loghin, M; Merrell, R; Paleologos, N; Phuphanich, S; Puduvalli, VK; Rademaker, A; Raizer, JJ; Rudnick, J; Tremont-Lukats, IW; Vaillant, B; Vick, N; Yuan, Y; Yung, WK	1
Heath, JR; Johnson, D; Su, Y; Wei, W; Xue, M	1
Heath, JR; Johnson, H; Kravchenko-Balasha, N; Levine, RD; White, FM	1
Cui, H; Hao, X; Wang, M; Wu, Y; Yang, R; Zhou, J; Zou, J	1
Bell, D; Garber, ST; Janku, F; Khoury, L; McCutcheon, IE; Schomer, DF	1
Aldape, K; Colman, H; Conrad, C; de Groot, JF; Gilbert, MR; Groves, MD; Hanna, TA; Hess, KR; Ictech, S; Levin, V; Puduvalli, VK; Yung, WK	1
Arusell, R; Brown, PD; Buckner, JC; Geoffroy, FJ; Giannini, C; Jaeckle, KA; Jenkins, RB; Kitange, G; Krishnan, S; Kugler, JW; Mischel, P; Morton, RF; Rowland, KM; Sarkaria, JN; Scheithauer, BW; Schiff, D; Uhm, JH; Wu, W; Yong, WH	1
Ayers-Ringler, J; Berger, MS; Butowski, N; Carliner, H; Chang, SM; DeBoer, R; Fedoroff, A; Haas-Kogan, DA; James, CD; Kabuubi, P; Lamborn, KR; McDermott, MW; Page, M; Parsa, AT; Parvataneni, R; Prados, MD; Rabbitt, J; Sneed, PK; Stokoe, D; Vandenberg, S	1
Armand, JP; Baurain, JF; Brandes, AA; Campone, M; Carpentier, AF; Clement, PM; Frenay, M; Gorlia, T; Kletzl, H; Klughammer, B; Kouwenhoven, MC; Kros, JM; Lacombe, D; Rampling, R; Taphoorn, MJ; Tosoni, A; van den Bent, MJ	1
Feuerhake, F; Halatsch, ME; Hielscher, T; Löw, S; Mursch, K; Schmidt, U; Unterberg, A; Vougioukas, VI	1
Hart, JR; Vogt, PK	1
Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Marcello, J; McLendon, RE; Norfleet, JA; Reardon, DA; Sampson, JH; Vredenburgh, JJ	1
Cornet, K; Foss, CA; Goodwin, CR; Kim, J; Lal, B; Laterra, J; Muzamil, S; Pomper, MG; Sang, Y	1
D'Elia, A; Formichella, AI; Frati, A; Salvati, M	1
Agarwal, N; Ahluwalia, MS; Barnett, GH; Brewer, CJ; Elson, P; Peereboom, DM; Shepard, DR; Stevens, GH; Suh, JH; Toms, SA; Vogelbaum, MA; Weil, RJ	1
Abrey, LE; Aldape, KD; Chang, SM; Cloughesy, TF; Dancey, J; Deangelis, LM; Fine, HA; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, M; Prados, MD; Raizer, JJ; Robins, HI; Wen, PY; Yung, WK	1
Abrey, LE; Aldape, KA; Chang, SM; Cloughesy, TF; Dancey, J; Deangelis, LM; Fine, HA; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, M; Prados, MD; Raizer, JJ; Robins, HI; Wen, PY; Yung, WK	1
Calles, A; Custodio, A; Pérez-Segura, P	1
Cloughesy, TF; Gilbert, MR; Klencke, B; Nghiemphu, P; Prados, MD; Reardon, DA; Vredenburgh, JJ; Yung, WK	1
Beyene, RT; Bleau, AM; Boockvar, JA; Gursel, DB; Holland, EC; Howard, BM	1
Airiau, K; Belaud-Rotureau, MA; Belloc, F; Eimer, S; Jeanneteau, M; Laharanne, E; Loiseau, H; Merlio, JP; Véron, N; Vital, A	1
Halatsch, ME; Karpel-Massler, G; Kast, RE; Westhoff, MA; Wirtz, CR	1
Kim, C; Lee, KB; Shah, BP; Subramaniam, P	1
Cavenee, WK; Furnari, F; Gonias, SL; Hu, J; Jo, M; VandenBerg, SR	1
Belden, CJ; Fadul, CE; Harris, BT; Israel, MA; Pastel, DA; Paulsen, K; Ran, C; Roberts, DW; Valdes, PA	1
Chao, YS; Cherniack, AD; Chiang, D; Cho, J; Dutt, A; Johnson, W; Kesari, S; Kwon, J; Meyerson, M; Onofrio, RC; Pastorino, S; Vandenberg, S; Verhaak, R; Watanabe, H; Xu, X; Yuza, Y; Zeng, Q	1
Bachoo, RM; Cavenee, WK; Dang, J; DePinho, RA; Fenton, TR; Furnari, FB; Inda, MM; Iwanami, A; James, CD; Kuga, D; Marie, SK; Mischel, PS; Nathanson, D; Oba-Shinjo, SM; Ponte de Albuquerque, C; Tanaka, K; Uno, M; Vandenberg, SR; Wykosky, J; Yang, H; Zhou, H	1
Boockvar, JA; Christos, P; Kaplan, R; Kesavabhotla, K; Lavi, E; Mubita, L; Pannullo, SC; Scheff, R; Schlaff, CD; Shin, B; Tsiouris, AJ	1
Airiau, K; Avril, T; Belaud-Rotureau, MA; Belloc, F; Dugay, F; Eimer, S; Quillien, V	1
Deng, ZL; Dong, YC; Han, QL; Jiang, T; Lv, XH; Ren, H; Xing, WJ; Zou, Y	1
Bianchi, F; Cenci, T; D'Alessandris, QG; Fernandez, E; Larocca, LM; Lauretti, L; Maira, G; Martini, M; Montano, N; Pallini, R	1
Ahluwalia, MS; Grossman, SA; Hilderbrand, SL; Mikkelsen, T; Nabors, LB; Peereboom, DM; Phuphanich, S; Rosenfeld, MR; Supko, JG; Ye, X	1
Wong, ET; Zhu, JJ	1
A-Borhani, F; Bötefür, IC; Buchfelder, M; Domhof, S; Efferth, T; Gebhart, E; Gehrke, EE; Halatsch, ME; Schmidt, U; Vougioukas, VI	1
Efferth, T; Gebhart, E; Halatsch, ME; Ramirez, T	1
Cappuzzo, F	1
Raizer, JJ	1
Bigner, DD; Friedman, HS	1
Beroukhim, R; Cavenee, WK; Chute, DJ; Cloughesy, TF; Dia, EQ; Haas-Kogan, DA; Horvath, S; Huang, JH; Lee, JC; Liau, LM; Lu, KV; Mellinghoff, IK; Mischel, PS; Peck, TC; Prados, M; Rao, PN; Riggs, BL; Sawyers, CL; Sellers, WR; Stokoe, D; Vivanco, I; Wang, MY; Yoshimoto, K; Zhu, S	1
Abrey, LE; Gilbert, MR; Lassman, AB	1
Behnke-Mursch, J; Halatsch, ME; Schmidt, U; Unterberg, A; Wirtz, CR	1
Ballman, KV; Brown, PD; Carlson, BL; Giannini, C; Grogan, P; Guha, A; James, CD; Kitange, GJ; Pandita, A; Sarkaria, JN; Schroeder, MA	1
Ballman, KV; Brown, PD; Buckner, JC; Fiveash, JB; Geoffroy, FJ; Giannini, C; Jaeckle, KA; Krishnan, S; Nabors, LB; Uhm, JH	1
Cavenee, WK; Cloughesy, TF; Dia, EQ; Lu, KV; Mellinghoff, IK; Mischel, PS; Sawyers, CL; Shackleford, GM; Vivanco, I; Wang, MY; Zhu, S	1
Beroukhim, R; Cloughesy, T; DeBiasi, RM; Feng, WL; Gabriel, S; Getz, G; Glatt, KA; Greulich, H; Huang, JH; Kawaguchi, T; Khan, H; King, JC; Leahy, DJ; Lee, JC; Levine, RL; Liau, LM; Linhart, DJ; Mellinghoff, IK; Meyerson, M; Mischel, P; Nelson, SF; Nghiemphu, P; O'Neill, K; Onofrio, R; Paez, JG; Peck, TC; Pieper, RO; Rao, PN; Sawyers, CL; Sellers, WR; Thomas, RK; Vivanco, I; Xu, Q; Yoshimoto, K; Yuza, Y; Ziaugra, L	1
Bai, F; Broniscer, A; Fraga, C; Gajjar, A; Krasin, MJ; O'Shaughnessy, M; Panetta, JC; Stewart, CF	1
Carlson, BL; Dinca, EB; Galanis, E; Giannini, C; Grogan, PT; James, CD; Kitange, GJ; Sarkaria, JN; Schroeder, MA; Wu, W; Yang, L	1
Bradner, JE; Brennan, C; Chin, L; DePinho, RA; Kimmelman, AC; Ligon, KL; Nabioullin, R; Ponugoti, AH; Stegh, AH; Stommel, JM; Wiedemeyer, R; Ying, H	1
Liau, LM; Salgaller, ML	1

Reviews

8 review(s) available for erlotinib hydrochloride and Glioblastoma

Article	Year
Erlotinib: early clinical development in brain cancer. Expert opinion on investigational drugs, 2014, Volume: 23, Issue:7 Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Protein Kinase Inhibitors; Quinazolines	2014
Insights into pharmacotherapy of malignant glioma in adults. Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:14 Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Erlotinib Hydrochloride; Glioblastoma; Glioma; Humans; Quinazolines; Temozolomide	2009
Erlotinib in glioblastoma: lost in translation? Anti-cancer agents in medicinal chemistry, 2011, Volume: 11, Issue:8 Topics: Animals; Brain Neoplasms; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Protein Kinase Inhibitors; Quinazolines	2011
Genetics of glioblastoma: a window into its imaging and histopathologic variability. Radiographics : a review publication of the Radiological Society of North America, Inc, 2011, Volume: 31, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cell Survival; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neovascularization, Pathologic; Phosphorylcholine; Protein Kinase Inhibitors; Quinazolines	2011
Personalized medicine for glioblastoma: current challenges and future opportunities. Current molecular medicine, 2013, Volume: 13, Issue:3 Topics: Cell Cycle; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Genetic Variation; Glioblastoma; Humans; Isocitrate Dehydrogenase; MicroRNAs; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Microenvironment	2013
HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. Journal of neuro-oncology, 2005, Volume: 74, Issue:1 Topics: Animals; Brain Neoplasms; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioblastoma; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction	2005
Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer treatment reviews, 2006, Volume: 32, Issue:2 Topics: Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioblastoma; Humans; Protein Kinase Inhibitors; Quinazolines	2006
Current status of clinical trials for glioblastoma. Reviews on recent clinical trials, 2006, Volume: 1, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Biocompatible Materials; Brain Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Decanoic Acids; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gefitinib; Glioblastoma; Humans; Imatinib Mesylate; Immunotoxins; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Piperazines; Polyesters; Protein Kinase Inhibitors; Proteins; Pyrimidines; Quinazolines; Sirolimus; Temozolomide; TOR Serine-Threonine Kinases; Transcription Factors	2006

Trials

17 trial(s) available for erlotinib hydrochloride and Glioblastoma

Article	Year
De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer discovery, 2013, Volume: 3, Issue:5 Topics: Adult; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Lapatinib; MAP Kinase Signaling System; Mice; Mice, SCID; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, Platelet-Derived Growth Factor beta; Transcription, Genetic; Tumor Burden; Xenograft Model Antitumor Assays	2013
A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma. Neuro-oncology, 2014, Volume: 16, Issue:7 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Quinazolines; Temozolomide; Young Adult	2014
A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. Journal of neuro-oncology, 2016, Volume: 126, Issue:1 Topics: Adult; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Radiotherapy; Temozolomide; Treatment Outcome; Young Adult	2016
Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. Journal of neuro-oncology, 2008, Volume: 90, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Carboplatin; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines	2008
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-01, Volume: 26, Issue:34 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Dacarbazine; Disease Progression; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Quinazolines; Radiotherapy; Temozolomide; Treatment Outcome	2008
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Feb-01, Volume: 27, Issue:4 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Erlotinib Hydrochloride; Glioblastoma; Gliosarcoma; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Temozolomide	2009
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Mar-10, Volume: 27, Issue:8 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; PTEN Phosphohydrolase; Quinazolines; Temozolomide	2009
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. Journal of neuro-oncology, 2010, Volume: 96, Issue:2 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Central Nervous System Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Treatment Outcome	2010
Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. Journal of neuro-oncology, 2010, Volume: 98, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Methylation; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiotherapy; Temozolomide; Tumor Suppressor Proteins; Young Adult	2010
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro-oncology, 2010, Volume: 12, Issue:1 Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Glioblastoma; Glioma; Humans; Male; Maximum Tolerated Dose; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Young Adult	2010
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro-oncology, 2010, Volume: 12, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glioblastoma; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Tissue Distribution	2010
Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro-oncology, 2010, Volume: 12, Issue:10 Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Genes, erbB-1; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines	2010
Phase I/II study of oral erlotinib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma. Journal of experimental therapeutics & oncology, 2012, Volume: 10, Issue:1 Topics: Adult; Aged; Anticonvulsants; Astrocytoma; Brain Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Recurrence	2012
Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience. Acta neurochirurgica, 2013, Volume: 155, Issue:1 Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Vascular Endothelial Growth Factor A	2013
NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. Neuro-oncology, 2013, Volume: 15, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Quinazolines; Sorafenib; Survival Rate; Tissue Distribution	2013
Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177. International journal of radiation oncology, biology, physics, 2006, Jul-15, Volume: 65, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Radiotherapy Dosage	2006
Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Mar-01, Volume: 13, Issue:5 Topics: Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Child; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Quinazolines	2007

Other Studies

63 other study(ies) available for erlotinib hydrochloride and Glioblastoma

Article	Year
Anti-glioblastoma effects of nanomicelle-curcumin plus erlotinib. Food & function, 2021, Nov-01, Volume: 12, Issue:21 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Curcumin; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Micelles; Nanostructures	2021
Combination Therapy with PIK3R3-siRNA and EGFR-TKI Erlotinib Synergistically Suppresses Glioblastoma Cell Growth In Vitro. Asian Pacific journal of cancer prevention : APJCP, 2021, Dec-01, Volume: 22, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Glioblastoma; Humans; Phosphatidylinositol 3-Kinases; RNA, Small Interfering	2021
CBX3 accelerates the malignant progression of glioblastoma multiforme by stabilizing EGFR expression. Oncogene, 2022, Volume: 41, Issue:22 Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromosomal Proteins, Non-Histone; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Ubiquitin-Protein Ligases; Ubiquitination	2022
The Marine-Derived Macrolactone Mandelalide A Is an Indirect Activator of AMPK. Marine drugs, 2022, Jun-27, Volume: 20, Issue:7 Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fibroblasts; Glioblastoma; Humans; Lung Neoplasms; Macrolides; Mammals; Mice; Phosphorylation	2022
Predicting Blood-Brain Barrier Permeation of Erlotinib and JCN037 by Molecular Simulation. The Journal of membrane biology, 2023, Volume: 256, Issue:2 Topics: Blood-Brain Barrier; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Lipids; Water	2023
Dual Targeting of EGFR and MTOR Pathways Inhibits Glioblastoma Growth by Modulating the Tumor Microenvironment. Cells, 2023, 02-08, Volume: 12, Issue:4 Topics: Animals; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Mammals; Mice; Phosphatidylinositol 3-Kinases; TOR Serine-Threonine Kinases; Tumor Microenvironment	2023
Cooperative Blockade of PKCα and JAK2 Drives Apoptosis in Glioblastoma. Cancer research, 2020, 02-15, Volume: 80, Issue:4 Topics: Acrylamides; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Indoles; Janus Kinase 2; Mice; Morpholines; Protein Kinase C-alpha; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays	2020
MiRNA-7 enhances erlotinib sensitivity of glioblastoma cells by blocking the IRS-1 and IRS-2 expression. The Journal of pharmacy and pharmacology, 2020, Volume: 72, Issue:4 Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Erlotinib Hydrochloride; Glioblastoma; Humans; Insulin Receptor Substrate Proteins; MicroRNAs	2020
Epidermal Growth Factor (EGF) Augments the Invasive Potential of Human Glioblastoma Multiforme Cells via the Activation of Collaborative EGFR/ROS-Dependent Signaling. International journal of molecular sciences, 2020, May-20, Volume: 21, Issue:10 Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Mitochondria; Reactive Oxygen Species; Signal Transduction	2020
Tailored therapy for recurrent glioblastoma: report of a personalized molecular approach. Journal of neurosurgical sciences, 2023, Volume: 67, Issue:1 Topics: Bevacizumab; Brain Neoplasms; Erlotinib Hydrochloride; Glioblastoma; Humans; Neoplasm Recurrence, Local; Vascular Endothelial Growth Factor A	2023
MiRNA-7 Replacement Effect on Proliferation and Tarceva-Sensitivity in U373-MG Cell Line. Asian Pacific journal of cancer prevention : APJCP, 2020, Jun-01, Volume: 21, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; MicroRNAs; Tumor Cells, Cultured	2020
Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation. Cell reports, 2017, 05-30, Volume: 19, Issue:9 Topics: Animals; Apoptosis; Cell Differentiation; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glioblastoma; Histones; Isocitrate Dehydrogenase; Ketoglutaric Acids; Lipids; Methylation; Mice; Mice, SCID; Molecular Targeted Therapy; Mutation; NADP; Neoplastic Stem Cells; Protein Kinase Inhibitors; Reactive Oxygen Species; RNA, Messenger	2017
Extracellular Hyaluronic Acid Influences the Efficacy of EGFR Tyrosine Kinase Inhibitors in a Biomaterial Model of Glioblastoma. Advanced healthcare materials, 2017, Volume: 6, Issue:21 Topics: Acrylamides; Animals; Biocompatible Materials; Brain Neoplasms; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Matrix; Gelatin; Glioblastoma; Humans; Hyaluronic Acid; Hydrogels; Matrix Metalloproteinase 2; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured; Up-Regulation	2017
Targeting of EGFR increase anti-cancer effects of arsenic trioxide: Promising treatment for glioblastoma multiform. European journal of pharmacology, 2018, Feb-05, Volume: 820 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; M Phase Cell Cycle Checkpoints; Molecular Targeted Therapy; Oxides; Reactive Oxygen Species	2018
Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells. Investigational new drugs, 2018, Volume: 36, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Erlotinib Hydrochloride; Glioblastoma; Humans; Piperazines; Pyridines; Retinoblastoma Protein; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Stem Cell Assay	2018
Design of a Multicompartment Hydrogel that Facilitates Time-Resolved Delivery of Combination Therapy and Synergized Killing of Glioblastoma. Angewandte Chemie (International ed. in English), 2018, 11-12, Volume: 57, Issue:46 Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Carriers; Drug Delivery Systems; Drug Synergism; Erlotinib Hydrochloride; Glioblastoma; Humans; Hydrogels; Peptides; Protein Kinase Inhibitors	2018
Co-delivery of doxorubicin and erlotinib through liposomal nanoparticles for glioblastoma tumor regression using an in vitro brain tumor model. Colloids and surfaces. B, Biointerfaces, 2019, Jan-01, Volume: 173 Topics: Antineoplastic Agents; Apoptosis; Biological Transport; Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Line, Tumor; Cell-Penetrating Peptides; Chitosan; Doxorubicin; Drug Delivery Systems; Endothelial Cells; Erlotinib Hydrochloride; Glioblastoma; Humans; Liposomes; Models, Biological; Neuroglia; Polylactic Acid-Polyglycolic Acid Copolymer; Protein Binding; Receptors, Transferrin; Tissue Scaffolds; Transferrin	2019
Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy: a case report. Acta neurochirurgica, 2018, Volume: 160, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Erlotinib Hydrochloride; Glioblastoma; Humans; Male; Neoplasm Recurrence, Local; Precision Medicine; Progression-Free Survival	2018
Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma. Nature communications, 2018, 11-21, Volume: 9, Issue:1 Topics: Animals; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Magnetic Resonance Imaging; Mice, Nude; Neoplasm Transplantation; Protein-Tyrosine Kinases; Sequence Analysis, RNA; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization	2018
The tumor suppressor FOXO3a mediates the response to EGFR inhibition in glioblastoma cells. Cellular oncology (Dordrecht), 2019, Volume: 42, Issue:4 Topics: Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Forkhead Box Protein O3; Glioblastoma; Humans; Phosphorylation; Protein Kinase Inhibitors; Transcriptional Activation; Trifluoperazine	2019
Dual functionalized liposomes for efficient co-delivery of anti-cancer chemotherapeutics for the treatment of glioblastoma. Journal of controlled release : official journal of the Controlled Release Society, 2019, 08-10, Volume: 307 Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cell-Penetrating Peptides; Doxorubicin; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Liposomes; Male; Mice, Nude; Nanoparticles; Phosphatidylethanolamines; Polyethylene Glycols; Tissue Distribution; Transferrin	2019
Hyaluronic acid-functionalized gelatin hydrogels reveal extracellular matrix signals temper the efficacy of erlotinib against patient-derived glioblastoma specimens. Biomaterials, 2019, Volume: 219 Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Matrix; Gelatin; Glioblastoma; Humans; Hyaluronan Receptors; Hyaluronic Acid; Hydrogels; Mice; Neoplasm Invasiveness; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; STAT3 Transcription Factor; Treatment Outcome; Tumor Microenvironment; Up-Regulation	2019
Arsenic reverses glioblastoma resistance to mTOR-targeted therapies. Cell cycle (Georgetown, Tex.), 2013, May-15, Volume: 12, Issue:10 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Leukemia, Promyelocytic, Acute; Oxides; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases	2013
Combined inhibition of HER1/EGFR and RAC1 results in a synergistic antiproliferative effect on established and primary cultured human glioblastoma cells. Molecular cancer therapeutics, 2013, Volume: 12, Issue:9 Topics: Aminoquinolines; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Mice, Inbred NOD; Molecular Targeted Therapy; Pyrimidines; Quinazolines; rac1 GTP-Binding Protein; Signal Transduction; Xenograft Model Antitumor Assays	2013
Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ. Neuro-oncology, 2013, Volume: 15, Issue:10 Topics: Animals; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Forkhead Transcription Factors; Gene Amplification; Glioblastoma; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Cells, Cultured	2013
Modulation of PPIX synthesis and accumulation in various normal and glioma cell lines by modification of the cellular signaling and temperature. Lasers in surgery and medicine, 2013, Volume: 45, Issue:7 Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Cytoplasm; Erlotinib Hydrochloride; Glioblastoma; Humans; Hypothermia, Induced; Mitochondria; Photochemotherapy; Photosensitizing Agents; Protein Kinase Inhibitors; Protoporphyrins; Quinazolines; Rats; Signal Transduction	2013
Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science (New York, N.Y.), 2014, Jan-03, Volume: 343, Issue:6166 Topics: Animals; Antineoplastic Agents; Central Nervous System Neoplasms; DNA; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Mice; Molecular Targeted Therapy; Mutation; Neoplasm Transplantation; Protein Kinase Inhibitors; Quinazolines; Single-Cell Analysis; Tumor Cells, Cultured; Withholding Treatment	2014
Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFα in glioblastoma. Science signaling, 2014, Aug-12, Volume: 7, Issue:338 Topics: Animals; Carcinogenesis; Drug Delivery Systems; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Glioblastoma; Humans; Immunoblotting; Immunohistochemistry; Immunoprecipitation; Kaplan-Meier Estimate; Mice; NF-kappa B; Paracrine Communication; Protein Kinase C; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tumor Necrosis Factor-alpha	2014
NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification. Molecular cancer therapeutics, 2014, Volume: 13, Issue:12 Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Gene Expression; Glioblastoma; Humans; Lapatinib; Mice; Quinazolines; Tissue Distribution; Xenograft Model Antitumor Assays	2014
Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab. Journal of neuro-oncology, 2015, Volume: 121, Issue:2 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain; Brain Neoplasms; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dacarbazine; Erlotinib Hydrochloride; Follow-Up Studies; Glioblastoma; Humans; Image Processing, Computer-Assisted; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Middle Aged; Outcome Assessment, Health Care; Prognosis; Quinazolines; Temozolomide; Young Adult	2015
A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma. Cancer research, 2015, Jan-15, Volume: 75, Issue:2 Topics: Animals; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glioblastoma; Heterografts; Humans; Membrane Proteins; Mice; Mice, Nude; Proto-Oncogene Proteins; Quinazolines; Receptors, Urokinase Plasminogen Activator; Signal Transduction	2015
Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib. International journal of cancer, 2015, Sep-15, Volume: 137, Issue:6 Topics: Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Mitogen-Activated Protein Kinases; Naphthoquinones; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction	2015
Chemical methods for the simultaneous quantitation of metabolites and proteins from single cells. Journal of the American Chemical Society, 2015, Apr-01, Volume: 137, Issue:12 Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Equipment Design; ErbB Receptors; Erlotinib Hydrochloride; Fluorescent Antibody Technique; Glioblastoma; Humans; Metabolomics; Microarray Analysis; Proteomics	2015
Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition. Targeted oncology, 2016, Volume: 11, Issue:1 Topics: Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Histone Deacetylase Inhibitors; Humans; Protein Kinase Inhibitors; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured	2016
Dose finding with longitudinal data: simpler models, richer outcomes. Statistics in medicine, 2015, Sep-30, Volume: 34, Issue:22 Topics: Antineoplastic Agents; Chemoradiotherapy; Child; Clinical Trials, Phase I as Topic; Computer Simulation; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Glioblastoma; Humans; Longitudinal Studies; Maximum Tolerated Dose; Models, Theoretical; Research Design	2015
Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma. Journal of translational medicine, 2015, Sep-17, Volume: 13 Topics: Animals; Autocrine Communication; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; Glioblastoma; Hepatocyte Growth Factor; Humans; Mice; Models, Biological; Molecular Targeted Therapy; Neoplasm Invasiveness; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Treatment Outcome; Xenograft Model Antitumor Assays	2015
Supramolecular Probes for Assessing Glutamine Uptake Enable Semi-Quantitative Metabolic Models in Single Cells. Journal of the American Chemical Society, 2016, Mar-09, Volume: 138, Issue:9 Topics: Brain Neoplasms; Carbocyanines; Cell Line, Tumor; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Fluorescence Resonance Energy Transfer; Glioblastoma; Glutamine; Humans; Molecular Probes	2016
A Thermodynamic-Based Interpretation of Protein Expression Heterogeneity in Different Glioblastoma Multiforme Tumors Identifies Tumor-Specific Unbalanced Processes. The journal of physical chemistry. B, 2016, 07-07, Volume: 120, Issue:26 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Computational Biology; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Genes, Reporter; Genetic Heterogeneity; Glioblastoma; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoplasm Proteins; Phosphoproteins; Signal Transduction; Thermodynamics	2016
The Hippo transducer TAZ promotes cell proliferation and tumor formation of glioblastoma cells through EGFR pathway. Oncotarget, 2016, Jun-14, Volume: 7, Issue:24 Topics: Animals; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Intracellular Signaling Peptides and Proteins; Male; Mice, Nude; Protein Kinase Inhibitors; RNA Interference; Signal Transduction; Trans-Activators; Transcription Factors; Transcriptional Coactivator with PDZ-Binding Motif Proteins; Transplantation, Heterologous	2016
Metastatic Adenoid Cystic Carcinoma Mimicking Butterfly Glioblastoma: A Rare Presentation in the Splenium of the Corpus Callosum. World neurosurgery, 2016, Volume: 95 Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Adenoid Cystic; Chemotherapy, Adjuvant; Corpus Callosum; Cranial Irradiation; Decompression, Surgical; Diagnosis, Differential; Erlotinib Hydrochloride; Glioblastoma; Humans; Kidney Neoplasms; Lung Neoplasms; Maintenance Chemotherapy; Male; Metastasectomy; Parotid Neoplasms; Radiotherapy, Adjuvant	2016
Candidate genes for sensitivity and resistance of human glioblastoma multiforme cell lines to erlotinib. Laboratory investigation. Journal of neurosurgery, 2009, Volume: 111, Issue:2 Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Expression; Genome-Wide Association Study; Glioblastoma; Humans; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction	2009
Akt demoted in glioblastoma. Science signaling, 2009, Apr-21, Volume: 2, Issue:67 Topics: Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Indoles; Maleimides; Models, Biological; Phosphorylation; Protein Kinase C-alpha; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Ribosomal Protein S6; Signal Transduction; TOR Serine-Threonine Kinases	2009
EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. Molecular cancer therapeutics, 2009, Volume: 8, Issue:7 Topics: Animals; Antibodies, Monoclonal; Brain Neoplasms; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Hepatocyte Growth Factor; Immunoblotting; Immunoenzyme Techniques; Mice; Mice, Knockout; Mice, Nude; Mice, SCID; Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays	2009
Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2010, Volume: 12, Issue:4 Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Goiter, Nodular; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; PTEN Phosphohydrolase; Quinazolines; Radiotherapy	2010
EGFR signaling is differentially activated in patient-derived glioblastoma stem cells. Journal of experimental therapeutics & oncology, 2010, Volume: 8, Issue:3 Topics: Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Tyrphostins	2010
Autophagy inhibition cooperates with erlotinib to induce glioblastoma cell death. Cancer biology & therapy, 2011, Jun-15, Volume: 11, Issue:12 Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Bcl-2-Like Protein 11; Caspases; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; HeLa Cells; Humans; Membrane Proteins; Mitochondria; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Signal Transduction	2011
Synergistic induction of apoptosis in brain cancer cells by targeted codelivery of siRNA and anticancer drugs. Molecular pharmaceutics, 2011, Oct-03, Volume: 8, Issue:5 Topics: Adjuvants, Pharmaceutic; Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Carriers; Drug Compounding; ErbB Receptors; Erlotinib Hydrochloride; Gene Silencing; Glioblastoma; Humans; Hydroxamic Acids; Ligands; Neoplasm Proteins; Particle Size; PC12 Cells; Quinazolines; Rats; RNA, Small Interfering; Vorinostat	2011
Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, Sep-20, Volume: 108, Issue:38 Topics: Animals; Antibiotics, Antineoplastic; Brain; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioblastoma; Humans; Immunoblotting; Mice; Mice, Nude; Mice, SCID; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor Cross-Talk; Receptors, Urokinase Plasminogen Activator; RNA Interference; STAT5 Transcription Factor; Transplantation, Heterologous; Tyrosine	2011
Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. Cancer research, 2011, Dec-15, Volume: 71, Issue:24 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gene Deletion; Glioblastoma; Humans; Kaplan-Meier Estimate; Mice; Mice, SCID; Mutation; NIH 3T3 Cells; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Tumor Burden; Xenograft Model Antitumor Assays	2011
Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proceedings of the National Academy of Sciences of the United States of America, 2012, Aug-28, Volume: 109, Issue:35 Topics: Animals; Astrocytes; Brain Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Mice; Mice, Mutant Strains; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured; Tyrosine	2012
Cyclopamine cooperates with EGFR inhibition to deplete stem-like cancer cells in glioblastoma-derived spheroid cultures. Neuro-oncology, 2012, Volume: 14, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Comparative Genomic Hybridization; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Glioblastoma; Humans; In Situ Hybridization, Fluorescence; Neoplastic Stem Cells; Quinazolines; Veratrum Alkaloids	2012
Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors. Clinical and experimental pharmacology & physiology, 2013, Volume: 40, Issue:1 Topics: Butadienes; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Furans; Gene Expression; Glioblastoma; Humans; Nitriles; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases	2013
Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines. Journal of neurosurgery, 2004, Volume: 100, Issue:3 Topics: Actins; Apoptosis; Cell Division; Cell Line, Tumor; Cell Movement; DNA Primers; DNA, Complementary; ErbB Receptors; Erlotinib Hydrochloride; Genes, p53; Glioblastoma; Humans; Immunohistochemistry; Polymerase Chain Reaction; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger	2004
Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774. Biochemical pharmacology, 2004, May-01, Volume: 67, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Artesunate; Cell Division; Cell Line; Cluster Analysis; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Nucleic Acid Hybridization; Quinazolines; Sesquiterpenes; Tumor Cells, Cultured	2004
Erlotinib in gliomas: should selection be based on EGFR and Akt analyses? Journal of the National Cancer Institute, 2005, Jun-15, Volume: 97, Issue:12 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Clinical Trials, Phase I as Topic; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Glioma; Humans; Lung Neoplasms; Mutation; Patient Selection; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines	2005
Glioblastoma multiforme and the epidermal growth factor receptor. The New England journal of medicine, 2005, Nov-10, Volume: 353, Issue:19 Topics: Amino Acid Sequence; Base Sequence; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Deletion; Gene Expression; Glioblastoma; Humans; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines	2005
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. The New England journal of medicine, 2005, Nov-10, Volume: 353, Issue:19 Topics: Adult; Aged; Antineoplastic Agents; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Amplification; Gene Deletion; Gene Expression; Genes, erbB-1; Genes, erbB-2; Glioblastoma; Humans; Male; Middle Aged; Mutation; Oligodendroglioma; Polymerase Chain Reaction; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Sequence Analysis, DNA; Signal Transduction	2005
Response of glioblastomas to EGFR kinase inhibitors. The New England journal of medicine, 2006, Feb-02, Volume: 354, Issue:5 Topics: ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Deletion; Glioblastoma; Humans; Phosphorylation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Signal Transduction	2006
Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Apr-01, Volume: 12, Issue:7 Pt 1 Topics: Adult; Aged; Animals; Combined Modality Therapy; Disease Models, Animal; Dose-Response Relationship, Radiation; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Glioblastoma; Humans; Male; Mice; Mice, Nude; Middle Aged; Quinazolines; Survival Rate; Transplantation, Heterologous; Xenograft Model Antitumor Assays	2006
Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer research, 2006, Aug-15, Volume: 66, Issue:16 Topics: Cell Division; Cell Line, Tumor; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Protein Kinases; PTEN Phosphohydrolase; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases; Transfection	2006
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS medicine, 2006, Volume: 3, Issue:12 Topics: Animals; Astrocytes; Binding Sites; Cell Line, Tumor; Cell Survival; Cells, Cultured; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; Mice, Nude; Models, Molecular; Mutation, Missense; Neoplasms, Experimental; NIH 3T3 Cells; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Transfection	2006
Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Molecular cancer therapeutics, 2007, Volume: 6, Issue:3 Topics: Animals; Antineoplastic Agents; Brain Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Survival Rate; Xenograft Model Antitumor Assays	2007
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (New York, N.Y.), 2007, Oct-12, Volume: 318, Issue:5848 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Indoles; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; PTEN Phosphohydrolase; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Signal Transduction; Sulfonamides	2007